July 2, 2012
The Ministry of Health, Labor and Welfare (MHLW) approved eight active pharmaceutical ingredients (API)/15 products including Pfizer Japan’s renal cell carcinoma treatment Inlyta Tablets 1 mg and 5 mg (axitinib) and Mitsubishi Tanabe Pharma Corporation’s DPP-4 (dipeptidyl peptidase-4) inhibitor Tenelia...read more